Table 1.
Duration of follow‐up and age at death (years) in long‐term followed participants with West syndrome
| Characteristic | Follow‐up time | Age at death | ||||||
|---|---|---|---|---|---|---|---|---|
| N | Mean (SD) | Md | Range | N (%) | Mean (SD) | Md | Range | |
| All | 207 | 32.5 (17.0) | 39.5 | 0.24–53.7 | 102 (49) | 19.1 (14.3) | 17.0 | 0.2–51.5 |
| Etiology | ||||||||
| Cryptogenic | 26 | 42.1 (13.4) | 48.5 | 7.6–53.7 | 4 (15) | 21.9 (20.0) | 14.8 | 7.6–50.6 |
| Symptomatic | 181 | 31.1 (17.0) | 38.6 | 0.2–53.1 | 98 (54) | 19.0 (14.1) | 17.0 | 0.2–51.5 |
| Sex | ||||||||
| Male | 126 | 31.7 (17.2) | 38.9 | 0.2–53.7 | 65 (52) | 18.5 (13.6) | 16.1 | 0.2–50.4 |
| Female | 81 | 33.8 (16.7) | 40.7 | 0.4–53.0 | 37 (46) | 20.2 (15.5) | 19.4 | 0.4–51.5 |
| ACTH treatment | ||||||||
| Yes | 161 | 33.7 (16.6) | 40.2 | 0.2–53.7 | 74 (46) | 19.3 (14.4) | 17.2 | 0.2–50.6 |
| No | 46 | 28.4 (18.0) | 27.7 | 1.0–53.3 | 28 (61) | 18.7 (14.2) | 15.8 | 1.0–51.5 |
ACTH, adrenocorticotropic hormone; Md, median; SD, standard deviation.